JP2019536426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536426A5 JP2019536426A5 JP2019510628A JP2019510628A JP2019536426A5 JP 2019536426 A5 JP2019536426 A5 JP 2019536426A5 JP 2019510628 A JP2019510628 A JP 2019510628A JP 2019510628 A JP2019510628 A JP 2019510628A JP 2019536426 A5 JP2019536426 A5 JP 2019536426A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cell
- cancer
- cell receptor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 and optionally Substances 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179862A JP7504853B2 (ja) | 2016-08-26 | 2021-11-02 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| JP2024095467A JP2024119949A (ja) | 2016-08-26 | 2024-06-12 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379864P | 2016-08-26 | 2016-08-26 | |
| DE102016115974 | 2016-08-26 | ||
| US62/379,864 | 2016-08-26 | ||
| DE102016115974.3 | 2016-08-26 | ||
| PCT/EP2017/071347 WO2018037085A1 (en) | 2016-08-26 | 2017-08-24 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179862A Division JP7504853B2 (ja) | 2016-08-26 | 2021-11-02 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536426A JP2019536426A (ja) | 2019-12-19 |
| JP2019536426A5 true JP2019536426A5 (enExample) | 2020-08-06 |
Family
ID=59738331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510628A Pending JP2019536426A (ja) | 2016-08-26 | 2017-08-24 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| JP2021179862A Active JP7504853B2 (ja) | 2016-08-26 | 2021-11-02 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| JP2024095467A Pending JP2024119949A (ja) | 2016-08-26 | 2024-06-12 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179862A Active JP7504853B2 (ja) | 2016-08-26 | 2021-11-02 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
| JP2024095467A Pending JP2024119949A (ja) | 2016-08-26 | 2024-06-12 | 頭頸部扁上皮がんおよびその他のがんに対する免疫療法で使用するための新規ペプチドおよびスキャフォールド |
Country Status (19)
| Country | Link |
|---|---|
| US (17) | US10376542B2 (enExample) |
| EP (2) | EP3504228A1 (enExample) |
| JP (3) | JP2019536426A (enExample) |
| KR (2) | KR20230128312A (enExample) |
| CN (2) | CN109803981B (enExample) |
| AU (2) | AU2017315139B2 (enExample) |
| BR (1) | BR112019003513A2 (enExample) |
| CA (1) | CA3033115A1 (enExample) |
| CL (4) | CL2019000460A1 (enExample) |
| CO (1) | CO2019002466A2 (enExample) |
| CR (4) | CR20210068A (enExample) |
| MA (1) | MA46037A (enExample) |
| MX (2) | MX2019002067A (enExample) |
| MY (1) | MY198110A (enExample) |
| PE (1) | PE20190628A1 (enExample) |
| PH (1) | PH12019500313A1 (enExample) |
| SG (2) | SG10202101871YA (enExample) |
| TW (2) | TW202304970A (enExample) |
| WO (1) | WO2018037085A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3319985T (pt) | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| TWI912273B (zh) * | 2019-12-30 | 2026-01-21 | 白素梅 | 人4IgB7-H3的突變編碼基因及其調節免疫的應用 |
| JP7822953B2 (ja) * | 2020-04-14 | 2026-03-03 | ウニヴェルシテ ド モントリオール | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN112245564A (zh) * | 2020-11-03 | 2021-01-22 | 哈尔滨医科大学 | 一种注射用血管生成抑肽冻干制剂及其冻干方法 |
| CN115403666B (zh) * | 2021-05-26 | 2025-08-12 | 中国农业大学 | 抗流感病毒多肽及其应用 |
| CN116200392B (zh) * | 2023-02-24 | 2026-08-11 | 杭州佰辰医学检验所有限公司 | 特异性结合丙戊酸钠小分子的核酸适配体、试剂盒及应用 |
| WO2025018697A1 (ko) * | 2023-07-14 | 2025-01-23 | 전남대학교산학협력단 | 암 진단을 위한 시료 처리 방법 및 이를 이용한 암 진단에 대한 정보 제공 방법 |
| WO2025257278A1 (en) * | 2024-06-12 | 2025-12-18 | Boehringer Ingelheim International Gmbh | Immunogenic sequences |
| CN118956629A (zh) * | 2024-07-24 | 2024-11-15 | 佳吾益(北京)科技有限公司 | 表达真正表位接受型mhc胞外结构域的工程化细胞 |
| CN120168640A (zh) * | 2025-05-23 | 2025-06-20 | 四川省医学科学院·四川省人民医院 | 抑制或沉默lap3活性的物质在制备治疗肿瘤和/或延缓李斯特菌浸入的药物中的应用 |
| CN121378411B (zh) * | 2025-10-27 | 2026-07-28 | 中国农业大学 | 一种用于防治结肠癌的小肽及其应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| US7235642B1 (en) * | 1999-01-12 | 2007-06-26 | Genentech, Inc. | Anti-PRO 1313 antibodies |
| CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1294748B1 (en) | 2000-03-27 | 2010-06-30 | Technion Research and Development of Foundation, Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| EP2322228B1 (en) | 2000-06-05 | 2018-01-10 | Altor BioScience Corporation | T cell receptor fusion proteins and conjugates and methods of use thereof |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| WO2003062391A2 (en) * | 2002-01-18 | 2003-07-31 | Incyte Corporation | Structural and cytoskeleton-associated proteins |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP2048159B1 (en) | 2002-11-09 | 2014-01-01 | Immunocore Ltd. | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| SI1760089T1 (sl) * | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US20100210829A1 (en) | 2007-03-08 | 2010-08-19 | Five Prime Therapeutics, Inc. | Compositions and Methods for Treating Diseases, Disorders, or Conditions Characterized by Myelin Degeneration, Myelin Deficiency or Loss |
| HUE025636T2 (en) * | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| WO2009036246A2 (en) * | 2007-09-14 | 2009-03-19 | Immunotope, Inc. | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer |
| EP2245054B1 (en) * | 2008-01-30 | 2018-11-28 | Pieris Pharmaceuticals GmbH | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| EP2283358B1 (en) * | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2632955A1 (en) | 2010-10-26 | 2013-09-04 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| WO2012148720A2 (en) * | 2011-04-27 | 2012-11-01 | The Regents Of The University Of California | Anti-microbial peptides and methods of use thereof |
| US10226238B2 (en) | 2011-09-12 | 2019-03-12 | Creatics Llc | Non-invasive methods of detecting target molecules |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US20150072922A1 (en) * | 2012-04-17 | 2015-03-12 | The Research Institute At Nationwide Children's Hospital | Rnase 7 antimicrobial peptides |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| WO2014168242A1 (ja) * | 2013-04-12 | 2014-10-16 | Jnc株式会社 | 歯周病特異的ペプチドに対するモノクローナル抗体およびその用途 |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201511792D0 (en) * | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| JP7405688B2 (ja) | 2020-05-14 | 2023-12-26 | 本田技研工業株式会社 | 情報処理装置、車両シェアリングシステム、情報処理方法、及びプログラム。 |
-
2017
- 2017-08-23 TW TW111136019A patent/TW202304970A/zh unknown
- 2017-08-23 TW TW106128506A patent/TWI796299B/zh not_active IP Right Cessation
- 2017-08-24 CA CA3033115A patent/CA3033115A1/en active Pending
- 2017-08-24 CR CR20210068A patent/CR20210068A/es unknown
- 2017-08-24 MA MA046037A patent/MA46037A/fr unknown
- 2017-08-24 MX MX2019002067A patent/MX2019002067A/es unknown
- 2017-08-24 JP JP2019510628A patent/JP2019536426A/ja active Pending
- 2017-08-24 SG SG10202101871YA patent/SG10202101871YA/en unknown
- 2017-08-24 MY MYPI2019000761A patent/MY198110A/en unknown
- 2017-08-24 CR CR20210066A patent/CR20210066A/es unknown
- 2017-08-24 KR KR1020237025497A patent/KR20230128312A/ko not_active Ceased
- 2017-08-24 SG SG11201901176XA patent/SG11201901176XA/en unknown
- 2017-08-24 CN CN201780051984.8A patent/CN109803981B/zh not_active Expired - Fee Related
- 2017-08-24 CN CN202411183035.3A patent/CN119060129A/zh active Pending
- 2017-08-24 KR KR1020197008490A patent/KR20190039812A/ko not_active Ceased
- 2017-08-24 AU AU2017315139A patent/AU2017315139B2/en not_active Ceased
- 2017-08-24 EP EP17758503.1A patent/EP3504228A1/en not_active Withdrawn
- 2017-08-24 CR CR20190094A patent/CR20190094A/es unknown
- 2017-08-24 BR BR112019003513-3A patent/BR112019003513A2/pt not_active Application Discontinuation
- 2017-08-24 CR CR20210067A patent/CR20210067A/es unknown
- 2017-08-24 PE PE2019000344A patent/PE20190628A1/es unknown
- 2017-08-24 EP EP21207150.0A patent/EP3988563A3/en not_active Withdrawn
- 2017-08-24 WO PCT/EP2017/071347 patent/WO2018037085A1/en not_active Ceased
- 2017-08-25 US US15/686,679 patent/US10376542B2/en active Active
-
2018
- 2018-10-16 US US16/162,337 patent/US10195232B1/en active Active
- 2018-12-27 US US16/234,458 patent/US10238691B1/en active Active
- 2018-12-28 US US16/235,147 patent/US10272114B1/en active Active
-
2019
- 2019-02-14 PH PH12019500313A patent/PH12019500313A1/en unknown
- 2019-02-20 MX MX2022002193A patent/MX2022002193A/es unknown
- 2019-02-21 CL CL2019000460A patent/CL2019000460A1/es unknown
- 2019-03-08 US US16/297,050 patent/US10688131B2/en active Active
- 2019-03-15 CO CONC2019/0002466A patent/CO2019002466A2/es unknown
- 2019-05-23 US US16/421,111 patent/US10525084B2/en active Active
- 2019-05-24 US US16/422,335 patent/US10596196B2/en active Active
-
2020
- 2020-01-23 US US16/750,908 patent/US10668100B1/en active Active
- 2020-04-03 US US16/839,984 patent/US10722536B1/en active Active
- 2020-04-17 US US16/852,189 patent/US10780125B2/en not_active Expired - Fee Related
- 2020-06-24 US US16/911,028 patent/US10842817B2/en not_active Expired - Fee Related
- 2020-10-21 US US17/076,261 patent/US11058726B2/en not_active Expired - Fee Related
-
2021
- 2021-03-05 CL CL2021000549A patent/CL2021000549A1/es unknown
- 2021-03-05 CL CL2021000550A patent/CL2021000550A1/es unknown
- 2021-03-05 CL CL2021000548A patent/CL2021000548A1/es unknown
- 2021-04-13 US US17/229,682 patent/US11123370B2/en active Active
- 2021-08-26 US US17/412,932 patent/US12221468B2/en active Active
- 2021-11-02 JP JP2021179862A patent/JP7504853B2/ja active Active
- 2021-12-10 AU AU2021282532A patent/AU2021282532B2/en not_active Ceased
-
2022
- 2022-06-10 US US17/837,807 patent/US12275775B2/en active Active
- 2022-06-17 US US17/843,887 patent/US12275776B2/en active Active
-
2024
- 2024-06-12 JP JP2024095467A patent/JP2024119949A/ja active Pending
-
2025
- 2025-01-10 US US19/016,523 patent/US20250223335A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516663A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2019515650A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2020506690A5 (enExample) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2019515653A5 (enExample) | ||
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2019520038A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2011520436A5 (enExample) | ||
| JP2021535900A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| JP2016501829A5 (enExample) | ||
| JP2019510465A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2017525336A5 (enExample) | ||
| FI3388075T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan | |
| JP2018536383A5 (enExample) | ||
| JP2020500523A5 (enExample) | ||
| ME02692B (me) | NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA | |
| AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer |